Carvacrol As a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article Publisher Pubmed



Zamanian MY^{1, 2} ; Kujawska M³ ; Nikbakhtzadeh M⁴ ; Hassanshahi A⁵ ; Ramezanpour S⁶ ; Kamiab Z^{7, 8} ; Bazmandegan G^{7, 8}
Source: CNS and Neurological Disorders - Drug Targets Published:2021

Abstract

Background and Objective: Neurological diseases are becoming a significant problem worldwide, with the elderly at a higher risk of being affected. Several researchers have investigated the neuroprotective effects of Carvacrol (CAR) (5-isopropyl-2-methyl phenol). This review system-atically surveys the existing literature on the impact of CAR when used as a neuroprotective agent in neurological diseases. Methods: The systematic review involved English articles published in the last ten years obtained from PubMed, Google Scholar, and Scopus databases. The following descriptors were used to search the literature: “Carvacrol” [Title] AND “neuroprotective (neuroprotection)” [Title] OR “stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, seizure, epilepsy [Title]. Results: A total of 208 articles were retrieved during the search process, but only 20 studies met the eligibility criteria and were included for review. A total of 20 articles were identified, in which the efficacy of CAR was described in experimental models of stroke, traumatic brain injury, Parkin-son’s disease, Alzheimer’s disease, epilepsy, and seizure, through motor deficits improvements in neurochemical activity, especially antioxidant systems, reducing inflammation, oxidative stress and apoptosis as well as inhibition of TRPC1 and TRPM7. Conclusion: The data presented in this study support the beneficial impact of CAR on behavioural and neurochemical deficits. CAR benefits accrue because of its anti-apoptotic, antioxidant, and an-ti-inflammatory properties. Therefore, CAR has emerged as an alternative treatment for neurological disorders based on its properties. © 2021 Bentham Science Publishers.